Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
about
Laparoscopic versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a single-center experience.Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook.Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals.Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery.When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.Early detection of pancreatic cancer: Where are we now and where are we going?Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer.Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Role of surgery in pancreatic cancerPrognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature.Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer.Home-based exercise during preoperative therapy for pancreatic cancer.Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications.The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma.Should Fear of Adverse Events Influence the Decision to Administer Preoperative Therapy to Patients with Pancreatic Cancer?Essential role of radiation therapy for the treatment of pancreatic cancer : Novel study concepts and established treatment recommendations.Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis.Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis.Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary BiologyWhat Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer.Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio.Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
P2860
Q33827828-730F8937-E40A-42A7-B60E-42FDFAE04B28Q37644113-7A29AE93-2775-4EA9-8948-67EBF40CDF5DQ38604415-D06C00E6-1CC2-4D55-8449-E0E670FFBA72Q38637958-ECDA6B7C-79AC-4E15-A108-B8F754A07EADQ38998202-DDD7F18D-017C-43D9-8F9E-C4B53C9AFE94Q39018587-2C3362F2-3AC6-479D-A4C3-345E78FF9A45Q39060622-35A6F0EA-3980-4DBB-882E-3F21804B1195Q39152619-EC80CECD-1B14-479C-BEBA-92DEC672A7A0Q39430849-A48C8EB4-F613-4A00-8789-BA3A7DCE0203Q41463557-DEDEE5A5-B8B4-4C91-81AA-979BA028EA34Q41651225-31B9B19A-4CD0-4F91-A9D6-29AFACAF5F23Q42339996-FA9B1664-B4F6-4408-A0C5-6F5745F30F95Q42700661-03A04CC3-4108-4375-8643-C0221A2A3423Q45304734-9E7FD26F-5700-43A8-A735-D4B5C026B5D0Q47816414-B0096736-A03E-4BAE-81D5-0EE4C17A9790Q48121758-18346870-6BC6-42BE-A581-B6DE9C699B28Q48169834-99D67D7A-FCC3-4787-8525-00B73F5F1D8BQ48221094-14F4DBD5-0B77-4774-BCBD-A5B1670D9F34Q48301473-F3C88938-E685-4C41-82A0-A58F9D19CDF2Q48599351-65EEB1F7-7F26-4297-97D8-F64C62C88DB4Q49832690-70AF30A9-69C5-4AF3-A6C7-AE7EEA2E5551Q50221174-91AE45A9-E750-4DD3-9ED8-EF560D98ECC9Q52578010-D2D11212-6A4E-41DD-9E29-7293AB2FED44Q52597920-3931CF55-4097-4961-AB9E-E774D7FF76DAQ52726017-32279D8E-CFA4-426F-8898-B6CEEF3B9AC1Q52875446-65C3D31B-6A8C-4BBB-8B3E-E06792B1ACE1Q54989340-FAB2FC13-5976-467E-9729-36927A84384EQ55251022-69B7B62D-828D-4931-A493-039AD04F90C1Q55441827-1721262F-CEF4-42C2-A100-75BEF44CCB3FQ58731700-D35E3042-A9B8-4F30-BEB3-4E683D805388
P2860
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Potentially Curable Pancreatic ...... y Clinical Practice Guideline.
@en
type
label
Potentially Curable Pancreatic ...... y Clinical Practice Guideline.
@en
prefLabel
Potentially Curable Pancreatic ...... y Clinical Practice Guideline.
@en
P2093
P356
P1476
Potentially Curable Pancreatic ...... y Clinical Practice Guideline.
@en
P2093
Anirban Maitra
Anitra Engebretson
Herbert J Zeh
Jordan Berlin
Marc Shapiro
Matthew H G Katz
Matthew Mumber
Pamela B Mangu
Richard Schulick
Supriya G Mohile
P304
P356
10.1200/JCO.2016.67.5553
P407
P577
2016-05-31T00:00:00Z